Home›Trastuzumab›Trastuzumab + Doxorubicin

Does Trastuzumab Interact with Doxorubicin?

CDI records a contraindicated classification for Trastuzumab and Doxorubicin. The stored summary is: Concomitant use results in increased risk of cardiac dysfunction. Do not administer in combination. Trastuzumab may persist for up to 7 months; avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification: Contraindicated
Trastuzumab Class: HER2/neu Receptor Antagonist
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Trastuzumab and your doctor is considering prescribing Doxorubicin (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask about alternative medications that do not interact with your current regimen
Ask how frequently you should be monitored while these are co-prescribed
Never stop or change either medication without first consulting your healthcare provider

💊 Trastuzumab(Herceptin)+💊 Doxorubicin(Doxorubicin Hydrochloride)

Severity & Interaction Details

⛔

contraindicated

Stored CDI classification: contraindicated

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

HER2/neu Receptor Antagonist

Drug B class

—

Source

NLP:doxorubicin

What this means in plain English

Concomitant use results in increased risk of cardiac dysfunction. Do not administer in combination. Trastuzumab may persist for up to 7 months; avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible.

About Trastuzumab and Doxorubicin

Trastuzumab is a HER2/neu Receptor Antagonist. Trastuzumab is also sold under the brand name Herceptin. Both Trastuzumab and Doxorubicin carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:doxorubicin

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Trastuzumab and Doxorubicin against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.